Key Highlights
- Robert J. Hombach joins Seaport Therapeutics’ Board of Directors and will chair the Audit Committee.
- Brings three decades of financial and operational leadership in healthcare.
- Former EVP, CFO, and COO of Baxalta (NYSE: BXLT); led its spin-off from Baxter.
- Serves on boards of BioMarin (NASDAQ: BMRN), Henry Schein (NASDAQ: HSIC), and Embecta (NASDAQ: EMBC).
- Recognized as a Top 100 US CFO by IR Magazine and a Board Leadership Fellow by NACD.
Source: Business Wire
Notable Quotes
- “We are excited to add Bob to our board. His financial and operational expertise perfectly complements the outstanding group of industry leaders on our board.” — Daphne Zohar, Founder & CEO at Seaport Therapeutics
- “Seaport is a new breed of company in a unique position to change the lives of patients with depression and anxiety disorders, and I am honored to contribute to its growth at such a pivotal time.” — Robert J. Hombach, Board Member at Seaport Therapeutics
Why This Matters
Seaport Therapeutics is at the forefront of developing novel neuropsychiatric medicines, addressing significant unmet needs in mental health. Bob Hombach’s appointment brings deep financial and operational expertise to the company, ensuring strong governance as it advances its pipeline of first- and best-in-class medicines. His leadership will be pivotal in driving Seaport’s growth and helping the company reach key milestones in its mission to deliver life-changing treatments for patients and their families.
